Although associated with improved clinical outcomes, insulin intensification as practiced in the UK has a relatively high cost per QALY and may not lead to cost-effective outcomes for patients with type 2 diabetes as currently defined by UK cost-effectiveness thresholds (Diabetes Research and Clinical Practice)
Diabetes News
Tag: insulin
Risk minimisation strategy for high strength and fixed 5 combination insulin products
Draft addendum to the good practice guide on risk minimisation and prevention of medication errors (European Medicines Agency)
Optimizing insulin injection technique and its effect on blood glucose control
Targeted individualized training in IT, including the switch to a 4 mm needle, is associated with improved glucose control, greater satisfaction with therapy, better and simpler injection practices and possibly lower consumption of insulin after only a three month period (Clinical and Translational Endocrinology)
Advanced preparation of insulin syringes for adult patients to administer at home
RCN guidance for nurses Second edition
Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat As Measured by Magnetic Resonance in Patients With Type 2 Diabetes
The administration of insulin glargine therapy reduced the liver fat burden in patients with type 2 diabetes. However, the improvements in the liver fat fraction and glycemia control were not significantly different from those in the liraglutide group (Diabetes Care)
Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain
In patients with type 2 diabetes insulin glargine administered by SoloSTAR® or ClikSTAR® pens, education on insulin injection and on self-management of diabetes was associated with clinically meaningful improvements in HbA1c and FPG without a mean collective weight gain. The vast majority of both patients and primary care physicians were satisfied with the treatment intensification (Swiss Medical Weekly)
Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT Study
HbA1c at the start of insulin therapy was the characteristic most predictive of later HbA1c, after accounting for other variables associated with HbA1c. This may provide some justification for earlier insulin introduction to improve glucose control to target (Diabetes Research and Clinical Practice)
Insulin Requirement Profiles of Short-term Intensive Insulin Therapy in Patients with Newly Diagnosed Type 2 Diabetes and Its Association with Long-term Glycemic Remission
There is a steady decline of TDD after euglycemia is achieved in patients with newly diagnosed type 2 diabetes treated with CSII, and and ΔTDD is associated with a better long-term glycemic outcome (Diabetes Research and Clinical Practice)
Sanofi receives FDA approval of once-daily basal insulin toujeo®
The U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of Q2 2015
Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis
In BOT, treatment persistence among type 2 diabetes patients initiating basal insulin is influenced by type of insulin, antidiabetic co-medication, and patient characteristics (Primary Care Diabetes)
Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates
The described work is to our knowledge the first demonstration of a glucose-binding modified insulin molecule with glucose-responsive activity verified in vivo (PNAS)
Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.
Afrezza is a drug-device combination product that consists of a dry formulation of human insulin delivered from a small and portable inhaler to help patients achieve blood sugar control (Sanofi)
An educational program for insulin self-adjustment associated with structured self-monitoring of blood glucose significantly improves glycemic control in patients with type 2 diabetes mellitus after 12 weeks
Training for self-titrating insulin doses combined with structured SMBG can safely improve glycemic control in poorly controlled insulin-treated T2DM patients
The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
Treatment with exenatide, with or without concomitant insulin was associated with reduced macrovascular risks compared to insulin; although inherent potential bias in epidemiological studies should be considered
Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs
Metformin can significantly reduce several adverse maternal and neonatal outcomes including PIH rate, incidence of hypoglycemia and NICU, thus it may be an effective and safe alternative or additional treatment to insulin for GDM women (Archives of Gynecology and Obstetrics)
Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control
Although the harms of intensive treatment likely exceed the benefits for older patients with complex/intermediate or very complex/poor health status, most of these adults reached tight glycemic targets between 2001 and 2010. Most of them were treated with insulin or sulfonylureas, which may lead to severe hypoglycemia. Our findings suggest that a substantial proportion of older adults with diabetes were potentially overtreated (JAMA Internal Medicine)
Insulin Cessation and Diabetes Remission After Bariatric Surgery in Insulin-Treated Type 2 Diabetic Adults
Insulin-treated type 2 diabetes patients have a greater probability of stopping insulin after RYGB than after LAGB (62% vs. 34%, respectively, at 1 year), with weight-independent effects in the early months after surgery. These findings support RYGB as the procedure of choice for reversing I-T2D (Diabetes Care)
Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients
Disordered early phase insulin and glucagon secretions but not incretin secretion are involved in hyperglycemia after ingestion of nutrients in T2DM of even a short duration (Journal of Diabetes and Its Complications)
- « Previous Page
- 1
- …
- 10
- 11
- 12
Glycosmedia is also available as an App: